Kane Biotech Expands Commercial Activities in the United States
Executive Summary
- Kane Biotech signed non‑exclusive U.S. distribution and sales agreements for its revyve® Antimicrobial Wound Gel product line with Patient Care Medical (Austin, TX) and Life Biologics (Lakewood, NJ).
- The agreements broaden the company’s presence in targeted geographic markets—Life Biologics will distribute nationally, while Patient Care Medical will cover Louisiana, Mississippi, and the Gulf Coast.
- Initial shipments are being prepared for the near term, supporting the company’s short‑term commercialization objectives.
Key Details
- Agreement Partners:
- Patient Care Medical – based in Austin, Texas; focuses on in‑hospital and mobile wound‑care facilities in Louisiana, Mississippi, and the Gulf Coast.
-
Life Biologics – based in Lakewood, New Jersey; distributes nationally within advanced wound‑care channels.
-
Product Covered: revyve® Antimicrobial Wound Gel® and revyve® Antimicrobial Wound Gel Spray (both U.S. FDA 510(k) cleared and Health Canada approved).
-
Distribution Model: Non‑exclusive, allowing each partner to sell the products within their defined territories and channels.
-
Commercial Timeline: Preparations underway for initial shipments in the near term; no specific launch date disclosed.
-
Strategic Rationale (CEO Quote): “Expanding our U.S. distribution network remains a key priority for the Company… these agreements enhance our access to selected U.S. markets and support our near‑term commercialization objectives.” – Dr. Robert Huizinga, Interim CEO.
-
Impact: Expands market reach in the United States, potentially increasing revenue streams as the company moves from development toward commercial sales.
Notable Quotes
“Expanding our U.S. distribution network remains a key priority for the Company,” said Dr. Robert Huizinga, Interim CEO of Kane Biotech. “These agreements enhance our access to selected U.S. markets and support our near‑term commercialization objectives.”